Women continue to be severely underrepresented in clinical trials on cardiovascular disease: today less than 30% participate in trials, a significant drop from the 40% recorded between 2010 and 2017. Raising the alarm is the Il Cuore Siamo Noi Foundation of the Italian Society of Cardiology (SIC), during a conference in the Senate dedicated to gender differences in cardiovascular risk. The data emerge from a study published in the British Medical Journal group's journal Heart, which analyzed more than 170 clinical trials, finding that women are systematically lower than men. This imbalance has serious consequences: the lack of specific data on women results in less effective therapies, more side effects, and lower adherence to treatments.